Coherus生物科技 CHRS 深 沪
等待开盘 02-05 09:30:00 美东时间
2.22
0.000
0.00%
华盛通- 最 高2.42
- 今 开2.28
- 成交量 207.07万股
- 最 低 2.18
- 昨 收 2.22
- 总市值 2.69亿
- 52周最高 2.6158
- 市盈率 静 8.94
- 换手率 1.71%
- 52周最低 0.71
- 委 比 -73.85%
- 总股本 1.21亿
- 历史最高 38.10
- 量 比 0.93
- 振 幅 10.81%
- 历史最低 0.6603
- 每 手 1
- 风险率 0.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/ -- Equity Insider News Commentary – The precision medicine sector is undergoing a structural realignment towa...
01-16 21:00
Coherus Oncology Publishes Preclinical And Clinical Biomarker Research In Molecular Cancer Therapeutics Describing The High Selectivity, Picomolar Binding Affinity And Significant Effector Mediated Killing Of CCR8+ Cells Of Its Investigational Anti-CCR8 Monoclonal Antibody;
Coherus Oncology, Inc. (NASDAQ:CHRS) today announced the publication of preclinical and clinical biomarker research in Molecular Cancer Therapeutics describing the high selectivity, picomolar binding affinity and
01-05 22:34
Coherus Oncology's LOQTORZI Plus Chemotherapy Nearly Doubles 6-Year Survival In Recurrent/Metastatic Nasopharyngeal Carcinoma
Coherus Oncology, Inc. (NASDAQ:CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus chemotherapy in
2025-12-08 21:48
SA Quant ranks Goldman's small-cap stocks with largest short interest
Goldman Sachs analysts last week identified 50 small-cap stocks with the highest short interest as a percentage of market cap, a list that was topped by Anavex Life Sciences (AVXL). The brokerage look...
2025-11-27 04:13
Coherus Oncology Presents New Multiomic Tumor And Blood-based Biomarker Data From Phase 1b Clinical Study Evaluation CHS-114 Antibody In Patients With Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma
Coherus Oncology, Inc. (NASDAQ: CHRS), today announced new multiomic tumor and blood-based biomarker data from the dose expansion arm of its ongoing Phase 1b clinical trial evaluating CHS-114, a selective, cytolytic
2025-11-07 22:16
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
Coherus Oncology Inc. (CHRS) announced that its third quarter 2025 financial results will be released after market close on November 6, 2025, followed by a conference call and webcast at 5:00 p.m. ET. The call will discuss financial results and provide a business update. Webcast replay and materials will be available at https://investors.coherus.com. Coherus uses this website for material non-public disclosures. The company specializes in oncolog...
2025-10-30 12:30
Coherus Oncology to Participate in Upcoming Investor Conferences
Coherus Oncology announced it will webcast its presentations at three upcoming conferences: the UBS Global Healthcare Conference on November 10, 2025; the Jefferies Global Healthcare Conference on November 18, 2025; and the Baird Biotech Discovery Series on December 17, 2025. Links to the webcasts and replays will be available on the company's Investor Events page.
2025-10-23 12:30
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals
4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.
2025-10-10 16:32
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Coherus Oncology will present CHS-114, an anti-CCR8 monoclonal antibody, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 8, 2025, in Maryland. Abstract #640 highlights its selective depletion of intratumoral Tregs and immune remodeling in advanced solid tumors. Additionally, CHS-114 will be featured in a SITC webinar on October 22, 2025, discussing CCR8's role in Treg activity and immunosuppression, with i...
2025-10-03 13:05
